We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 12, 2021

Nivolumab Combined With Paclitaxel Plus Ramucirumab as Second-Line Treatment in Advanced Gastric Cancer

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Multicenter Phase I/II Study of Nivolumab Combined With Paclitaxel Plus Ramucirumab as Second-Line Treatment in Patients With Advanced Gastric Cancer
Clin. Cancer Res 2020 Dec 01;[EPub Ahead of Print], TE Nakajima, S Kadowaki, K Minashi, T Nishina, T Yamanaka, Y Hayashi, N Izawa, K Muro, S Hironaka, T Kajiwara, Y Kawakami

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading